These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 26385421)

  • 21. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.
    van der Post RS; Kiemeney LA; Ligtenberg MJ; Witjes JA; Hulsbergen-van de Kaa CA; Bodmer D; Schaap L; Kets CM; van Krieken JH; Hoogerbrugge N
    J Med Genet; 2010 Jul; 47(7):464-70. PubMed ID: 20591884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for Lynch syndrome.
    Zighelboim I; Powell MA; Babb SA; Whelan AJ; Schmidt AP; Clendenning M; Senter L; Thibodeau SN; de la Chapelle A; Goodfellow PJ
    Fam Cancer; 2009; 8(4):501-4. PubMed ID: 19672700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic mechanisms in the pathogenesis of Lynch syndrome.
    Peltomäki P
    Clin Genet; 2014 May; 85(5):403-12. PubMed ID: 24443998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nine novel pathogenic germline mutations in MLH1, MSH2, MSH6 and PMS2 in families with Lynch syndrome.
    Rahner N; Friedrichs N; Wehner M; Steinke V; Aretz S; Friedl W; Buettner R; Mangold E; Propping P; Walldorf C
    Acta Oncol; 2007; 46(6):763-9. PubMed ID: 17653898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
    Bonadona V; Bonaïti B; Olschwang S; Grandjouan S; Huiart L; Longy M; Guimbaud R; Buecher B; Bignon YJ; Caron O; Colas C; Noguès C; Lejeune-Dumoulin S; Olivier-Faivre L; Polycarpe-Osaer F; Nguyen TD; Desseigne F; Saurin JC; Berthet P; Leroux D; Duffour J; Manouvrier S; Frébourg T; Sobol H; Lasset C; Bonaïti-Pellié C;
    JAMA; 2011 Jun; 305(22):2304-10. PubMed ID: 21642682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative diagnosis of Lynch syndrome with DNA mismatch repair immunohistochemistry on a diagnostic biopsy.
    Warrier SK; Trainer AH; Lynch AC; Mitchell C; Hiscock R; Sawyer S; Boussioutas A; Heriot AG
    Dis Colon Rectum; 2011 Dec; 54(12):1480-7. PubMed ID: 22067175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2).
    Rahner N; Steinke V; Schlegelberger B; Olschwang S; Eisinger F; Hutter P
    Eur J Hum Genet; 2010 Sep; 18(9):. PubMed ID: 20104243
    [No Abstract]   [Full Text] [Related]  

  • 28. Tumor Screening and DNA Testing in the Diagnosis of Lynch Syndrome.
    Usha L; Dewdney SB; Buckingham LE
    JAMA; 2016 Jul; 316(1):93-4. PubMed ID: 27380347
    [No Abstract]   [Full Text] [Related]  

  • 29. Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population.
    Ito T; Kono K; Eguchi H; Okazaki Y; Yamamoto G; Tachikawa T; Akagi K; Okada Y; Kawakami S; Morozumi M; Tamaru JI; Ishida H
    Jpn J Clin Oncol; 2020 Jan; 50(1):80-88. PubMed ID: 31665498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndrome.
    Jensen UB; Sunde L; Timshel S; Halvarsson B; Nissen A; Bernstein I; Nilbert M
    Breast Cancer Res Treat; 2010 Apr; 120(3):777-82. PubMed ID: 19575290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunohistochemical examination of MSH2, PMS2, MLH1, MSH6 compared with the analysis of microsatellite instability in colon adenocarcinoma].
    Raskin GA; Ianus GA; Kornilov AV; Orlova RV; Petrov SV; Protasova AÉ; Pozharisskiĭ KM; Imianitov EN
    Vopr Onkol; 2014; 60(2):47-50. PubMed ID: 24919261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PMS2 involvement in patients suspected of Lynch syndrome.
    Niessen RC; Kleibeuker JH; Westers H; Jager PO; Rozeveld D; Bos KK; Boersma-van Ek W; Hollema H; Sijmons RH; Hofstra RM
    Genes Chromosomes Cancer; 2009 Apr; 48(4):322-9. PubMed ID: 19132747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA mismatch repair abnormalities in acinar cell carcinoma of the pancreas: frequency and clinical significance.
    Liu W; Shia J; Gönen M; Lowery MA; O'Reilly EM; Klimstra DS
    Pancreas; 2014 Nov; 43(8):1264-70. PubMed ID: 25058881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome.
    Guindalini RS; Win AK; Gulden C; Lindor NM; Newcomb PA; Haile RW; Raymond V; Stoffel E; Hall M; Llor X; Ukaegbu CI; Solomon I; Weitzel J; Kalady M; Blanco A; Terdiman J; Shuttlesworth GA; Lynch PM; Hampel H; Lynch HT; Jenkins MA; Olopade OI; Kupfer SS
    Gastroenterology; 2015 Nov; 149(6):1446-53. PubMed ID: 26248088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lynch syndrome in a 15-year-old boy.
    Bodas A; Pérez-Segura P; Maluenda C; Caldés T; Olivera E; Díaz-Rubio E
    Eur J Pediatr; 2008 Oct; 167(10):1213-5. PubMed ID: 18183421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
    Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
    Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair.
    Case AS; Zighelboim I; Mutch DG; Babb SA; Schmidt AP; Whelan AJ; Thibodeau SN; Goodfellow PJ
    Gynecol Oncol; 2008 Feb; 108(2):438-44. PubMed ID: 18022218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.
    Ait Ouakrim D; Dashti SG; Chau R; Buchanan DD; Clendenning M; Rosty C; Winship IM; Young JP; Giles GG; Leggett B; Macrae FA; Ahnen DJ; Casey G; Gallinger S; Haile RW; Le Marchand L; Thibodeau SN; Lindor NM; Newcomb PA; Potter JD; Baron JA; Hopper JL; Jenkins MA; Win AK
    J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26109217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers.
    Lawes DA; Pearson T; Sengupta S; Boulos PB
    Br J Cancer; 2005 Aug; 93(4):472-7. PubMed ID: 16106253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risks of less common cancers in proven mutation carriers with lynch syndrome.
    Engel C; Loeffler M; Steinke V; Rahner N; Holinski-Feder E; Dietmaier W; Schackert HK; Goergens H; von Knebel Doeberitz M; Goecke TO; Schmiegel W; Buettner R; Moeslein G; Letteboer TG; Gómez García E; Hes FJ; Hoogerbrugge N; Menko FH; van Os TA; Sijmons RH; Wagner A; Kluijt I; Propping P; Vasen HF
    J Clin Oncol; 2012 Dec; 30(35):4409-15. PubMed ID: 23091106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.